CXCL12 and triple-A syndrome: Our study validates that inhibiting the CXCL12/CXCR4 axis can mitigate AAA progression and lower rupture risk, as evidenced by both in vivo and in vitro experiments, highlighting the therapeutic potential of CXCR4 targeting for AAA management.